The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 8, 2023. Its latest SEC filing is a 15-12G from Oct 6, 2023.
10-Q for Q2 FY2023, filed Aug 8, 2023
The sections below describe the company as of the FY2022 annual report.
Develops and commercializes small-molecule therapies for patients with severe diseases, including Friedreich’s ataxia and rare kidney diseases.
10-K for FY2022, filed Feb 24, 2023We are a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies that change…View ↗
Historically, revenue came mainly from upfront and milestone payments under drug-license collaborations and expense reimbursements. Partners may also owe royalties when licensed drugs are sold; some upfront license fees are spread across the agreement term.
10-K for FY2022, filed Feb 24, 2023Our revenue to date has been generated primarily from licensing fees received under our collaborative license agreements and reimbursements…View ↗
The Company’s revenue to date has been generated primarily from licensing fees received under its collaborative licensing agreements with…View ↗
Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the…View ↗
$2.2M
10-K for FY2022, filed Feb 24, 2023
$2.2M ↗
Drug-company partners license development and commercialization rights; Kyowa Kirin develops bardoxolone in its licensed markets. For products Reata commercializes itself, its planned specialty team targets physicians and uses specialty pharmacies and distribution channels.
10-K for FY2022, filed Feb 24, 2023OverviewView ↗
We are prepared to deploy our commercial team for launch of omaveloxolone at approval in the United States and have established the…View ↗
Commercial infrastructure for orphan products typically consists of a targeted, specialty sales force that calls on a limited and focused…View ↗
In December 2009, we entered into an agreement with Kyowa Kirin, under which we provided Kyowa Kirin the right to develop and commercialize…View ↗
No. It lost $311.9M in FY2022.
10-Q for Q2 FY2023, filed Aug 7, 2023
$193MView ↗
8-K, filed Sep 26, 2023
Concurrently with the closing of the Merger, on the Closing Date, Biogen prepaid all outstanding term loans advanced by the lenders under…View ↗
Shrank. Revenue fell 96% in 4 years, from $53.6M in FY2018 to $2.2M in FY2022, about 55% a year.
Omaveloxolone advanced toward launch
Omaveloxolone moved from a planned regulatory filing to an application under review, while Reata prepared a commercial team and distribution setup for a U.S. launch.
10-K for FY2019, filed Feb 19, 2020 10-K for FY2022, filed Feb 24, 2023In October 2019, we announced that the registrational part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with FA met…View ↗
Bardoxolone's Alport path stalled
After planning a U.S. filing following trial results, Reata reported that the U.S. regulator could not approve bardoxolone's application in its current form and withdrew the European application.
10-K for FY2019, filed Feb 19, 2020 10-K for FY2022, filed Feb 24, 2023In November 2019, we announced that the Phase 3 portion of the CARDINAL study of bardoxolone in patients with CKD caused by Alport syndrome…View ↗
Competes with PTC Therapeutics, Minoryx Therapeutics, MetroBiotech, Jupiter Neurosciences, Stealth BioTherapeutics, Larimar Therapeutics, Design Therapeutics, Lexeo Therapeutics, Biohaven Pharmaceutical Holding, Medtronic, Abbott, Nevro, DyAnsys, Daiichi Sankyo, Helixmith, Sichuan Haisco Pharmaceutical, Lexicon Pharmaceuticals, AstraZeneca, Mitsubishi Tanabe Pharma, and Pure Green Pharmaceuticals
10-K for FY2022, filed Feb 24, 2023We are aware of only one program, vatiquinone from PTC Therapeutics Inc., in Phase 3 stage of development. Additionally, competitor product…View ↗
Loading...
